Collaboration for wound care treatment

You are here

Lyon, Cleveland, June 27th, 2017 - AMOEBA announced today the development of a collaboration with VISCUS BIOLOGICS in order to carry out collective testing on a new wound care application in the field of human health.

VISCUS BIOLOGICS has a proven expertise in the field of wound care products, in particular collagen-based dressings. Following preliminary in vitro testing, the two companies intend to extend their cooperation and further confirm, through additional in vitro and in vivo testing, the action of the Willaertia magna C2c Maky micro-organism against certain pathogenic Multi-Drug Resistant (MDR) bacteria that resist multiple antibiotics.  Willaertia magna C2c Maky could therefore be used with advanced wound care dressings. This project is in the first instance focusing on the US market.

In a global advanced wound care market estimated at USD 17 billion1, the antimicrobial dressing segment represents USD 1.87 billion2 with a potential CAGR of USD 841 million3 in the USA.

« With this project with AMOEBA, VISCUS BIOLOGICS is aiming to address a very important market segment in the wound care industry.  Ultimately, Willaertia magna C2c Maky on its own or in combination with other treatments may provide another tool for treating wounds that are infected or at risk of becoming infected. » stated Peter GINGRAS, CEO of VISCUS BIOLOGICS.

« With this collaboration with VISCUS BIOLOGICS, AMOEBA is reaching an historical turning point in its development. We will be able to contribute to the advancement of clinical research to meet the global challenge of bacterial resistance to antibiotics (chemical molecules). Preliminary in vitro testing supports the use of Willaertia Magna C2c Maky on antibiotic-resistant strains. This partnership opens new development perspectives for AMOEBA beyond water treatment, in the chronic wound care market. » added Fabrice PLASSON, CEO of AMOEBA.

Related Posts